Ravenel Boykin Curry IV
Eagle Capital Management
Eagle Capital Management Constellation Pharmaceuticals Inc stake
total: 177
Eagle Capital Management CNST trades
- Total transactions:
- 4
- New positions:
- 2
- Sold out:
- 2
- Held since:
- 2020 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2021 Q2
According to 2026 Q2 report, Eagle Capital Management doesn't hold any Constellation Pharmaceuticals Inc (CNST) shares. To date, the estimated cost basis is nearly $28.82 for "buy" trades and estimated average "sell" price is $23.38. Eagle Capital Management first purchased CNST in 2019 Q4, initially acquiring 8,639 shares. Eagle Capital Management later completely sold out the position and invested in Constellation Pharmaceuticals Inc again in 2020 Q4. Since the initial investment in Constellation Pharmaceuticals Inc (CNST), Eagle Capital Management has made 3 more transactions.
When did Eagle Capital Management sell Constellation Pharmaceuticals Inc (CNST)?
Eagle Capital Management sold off the entire Constellation Pharmaceuticals Inc (CNST) position in 2021 Q2.
When did Eagle Capital Management buy Constellation Pharmaceuticals Inc (CNST)?
Eagle Capital Management first invested in Constellation Pharmaceuticals Inc (CNST) in 2019 Q4 at the reported quarter-end price of $47.11 per share.
What's the cost basis of Eagle Capital Management's CNST stake?
The estimated cost basis for Constellation Pharmaceuticals Inc (CNST) stake is around $28.82 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $28.82
- Weighted AVG sell price:
- $23.38
Eagle Capital Management's historical trades in Constellation Pharmaceuticals Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$23.38
|
|
-100% (-8,639)
|
-0%
|
|
2020 Q4
|
0.00%
|
$28.82
|
new
|
|||
|
2020 Q3
|
0.00%
|
$30.10
|
-100% (-8,639)
|
|||
|
2019 Q4
|
0.00%
|
$47.11
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.